Literature DB >> 16630034

The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study.

M G Law1, N Friis-Møller, W M El-Sadr, R Weber, P Reiss, A D'Arminio Monforte, R Thiébaut, L Morfeldt, S De Wit, C Pradier, G Calvo, O Kirk, C A Sabin, A N Phillips, J D Lundgren.   

Abstract

BACKGROUND: The D:A:D (Data Collection on Adverse Events of Anti-HIV Drugs) Study, a prospective observational study on a cohort of 23 468 patients with HIV infection, indicated that the incidence of myocardial infarction (MI) increased by 26% per year of exposure to combination antiretroviral treatment (CART). However, it remains unclear whether the observed increase in the rate of MI in this population can be attributed to changes in conventional cardiovascular risk factors.
OBJECTIVE: To compare the number of MIs observed among participants in the D:A:D Study with the number predicted by assuming that conventional cardiovascular risk equations apply to patients with HIV infection.
METHODS: The Framingham equation, a conventional cardiovascular risk algorithm, was applied to individual patient data in the D:A:D Study to predict rates of MI by duration of CART. A series of sensitivity analyses were performed to assess the effect of model and data assumptions. Predictions were extrapolated to provide 10-year risk estimates, and various scenarios were modelled to assess the expected effect of different interventions.
RESULTS: In patients receiving CART, the observed numbers of MIs during D:A:D follow up were similar to or somewhat higher than predicted numbers: 9 observed vs 5.5 events predicted, 14 vs 9.8, 22 vs 14.9, 31 vs 23.2 and 47 vs 37.0 for<1 year, 1-2 years, 2-3 years, 3-4 years and >4 years CART exposure, respectively. In patients who had not received CART, the observed number of MIs was fewer than predicted (3 observed vs 7.6 predicted). Nine per cent of the study population have a predicted 10-year risk of MI above 10%, a level usually associated with initiation of intervention on risk factors.
CONCLUSIONS: A consistent feature of all analyses was that observed and predicted rates of MI increased in a parallel fashion with increased CART duration, suggesting that the observed increase in risk of MI may at least in part be explained by CART-induced changes in conventional risk factors. These findings provide guidance in terms of choosing lifestyle or therapeutic interventions to decrease those risk factors in much the same way as in persons without HIV infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16630034     DOI: 10.1111/j.1468-1293.2006.00362.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  91 in total

Review 1.  Dyslipidemia and its Treatment in HIV Infection.

Authors:  Carl Grunfeld
Journal:  Top HIV Med       Date:  2010 Aug-Sep

2.  HIV and general cardiovascular risk.

Authors:  Bernadette Capili; Joyce K Anastasi; Olugbenga Ogedegbe
Journal:  J Assoc Nurses AIDS Care       Date:  2011-02-01       Impact factor: 1.354

Review 3.  Management of the metabolic effects of HIV and HIV drugs.

Authors:  Todd T Brown; Marshall J Glesby
Journal:  Nat Rev Endocrinol       Date:  2011-09-20       Impact factor: 43.330

4.  Antiretroviral therapy and cardiovascular risk.

Authors:  E Ridha; E Devitt; M Boffito; F Boag
Journal:  BMJ Case Rep       Date:  2011-02-24

5.  Lipoprotein-associated phospholipase A2 and cardiovascular disease risk in HIV infection.

Authors:  A Ross Eckard; C T Longenecker; Y Jiang; S M Debanne; D Labbato; N Storer; G A McComsey
Journal:  HIV Med       Date:  2014-03-20       Impact factor: 3.180

6.  State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary.

Authors:  Steven K Grinspoon; Carl Grunfeld; Donald P Kotler; Judith S Currier; Jens D Lundgren; Michael P Dubé; Steven E Lipshultz; Priscilla Y Hsue; Kathleen Squires; Morris Schambelan; Peter W F Wilson; Kevin E Yarasheski; Colleen M Hadigan; James H Stein; Robert H Eckel
Journal:  Circulation       Date:  2008-06-19       Impact factor: 29.690

7.  Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy.

Authors:  Judith S Currier; Jens D Lundgren; Andrew Carr; Daniel Klein; Caroline A Sabin; Paul E Sax; Jeffrey T Schouten; Marek Smieja
Journal:  Circulation       Date:  2008-06-19       Impact factor: 29.690

Review 8.  Metabolic syndrome, diabetes, and cardiovascular risk in HIV.

Authors:  Linda M Nix; Phyllis C Tien
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

9.  ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease): developed in collaboration with the American Academy of Neurology; American Association of Cardiovascular and Pulmonary Rehabilitation; American College of Preventive Medicine; American College of Sports Medicine; American Diabetes Association; American Society of Hypertension; Association of Black Cardiologists; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute; National Lipid Association; and Preventive Cardiovascular Nurses Association.

Authors:  C Noel Bairey Merz; Mark J Alberts; Gary J Balady; Christie M Ballantyne; Kathy Berra; Henry R Black; Roger S Blumenthal; Michael H Davidson; Sara B Fazio; Keith C Ferdinand; Lawrence J Fine; Vivian Fonseca; Barry A Franklin; Patrick E McBride; George A Mensah; Geno J Merli; Patrick T O'Gara; Paul D Thompson; James A Underberg
Journal:  J Am Coll Cardiol       Date:  2009-09-29       Impact factor: 24.094

10.  HIV infection and the risk of acute myocardial infarction.

Authors:  Matthew S Freiberg; Chung-Chou H Chang; Lewis H Kuller; Melissa Skanderson; Elliott Lowy; Kevin L Kraemer; Adeel A Butt; Matthew Bidwell Goetz; David Leaf; Kris Ann Oursler; David Rimland; Maria Rodriguez Barradas; Sheldon Brown; Cynthia Gibert; Kathy McGinnis; Kristina Crothers; Jason Sico; Heidi Crane; Alberta Warner; Stephen Gottlieb; John Gottdiener; Russell P Tracy; Matthew Budoff; Courtney Watson; Kaku A Armah; Donna Doebler; Kendall Bryant; Amy C Justice
Journal:  JAMA Intern Med       Date:  2013-04-22       Impact factor: 21.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.